1
|
Xie X, Ji J, Chen X, Xu W, Chen H, Zhu S, Wu J, Wu Y, Sun Y, Sai W, Liu Z, Xiao M, Bao B. Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3. Clin Transl Oncol 2022; 24:517-531. [PMID: 34811696 DOI: 10.1007/s12094-021-02705-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 08/31/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignant tumors of the digestive system. Many patients are diagnosed at an advanced stage and lose eligibility for surgery. Moreover, there are few effective methods for treating pancreatic ductal cell carcinoma. Increasing attention has been given to microRNAs (miRNAs) and their regulatory roles in tumor progression. In this study, we investigated the effects of exosomes extracted from human umbilical cord mesenchymal stem cells (HUCMSCs) carrying hsa-miRNA-128-3p on pancreatic cancer cells. METHODS Based on existing experimental and database information, we selected Galectin-3, which is associated with pancreatic cancer, and the corresponding upstream hsa-miRNA-128-3p. We extracted HUCMSCs from a fresh umbilical cord, hsa-miRNA-128-3p was transfected into HUCMSCs, and exosomes containing hsa-miRNA-128-3p were extracted and collected. The effect of exosomes rich in hsa-miRNA-128-3p on pancreatic cancer cells was analyzed. RESULTS The expression of Galectin-3 in normal pancreatic duct epithelial cells was significantly lower than that in PDAC cell lines. We successfully extracted HUCMSCs from the umbilical cord and transfected hsa-miRNA-128-3p into HUCMSCs. Then we demonstrated that HUCMSC-derived exosomes with hsa-miRNA-128-3p could suppress the proliferation, invasion, and migration of PANC-1 cells in vitro by targeting Galectin-3. CONCLUSION Hsa-miRNA-128-3p could be considered as a potential therapy for pancreatic cancer. We provided a new idea for targeted therapy of PDAC.
Collapse
Affiliation(s)
- X Xie
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - J Ji
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - X Chen
- Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
| | - W Xu
- Department of Gastroenterology, Second People's Hospital of Nantong, Nantong, 226001, China
| | - H Chen
- Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
| | - S Zhu
- Medical School of Nantong University Oral Medicine, Nantong, 226001, Jiangsu, China
| | - J Wu
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - Y Wu
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - Y Sun
- Blood Center of Jiangsu Province, Nanjing, 210000, Jiangsu, China
| | - W Sai
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China
| | - Z Liu
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China
| | - M Xiao
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
| | - B Bao
- Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, 226001, Jiangsu, China.
| |
Collapse
|
3
|
Schirrmacher V. Biotherapy of cancer. Perspectives of immunotherapy and gene therapy. J Cancer Res Clin Oncol 1995; 121:443-51. [PMID: 7642685 DOI: 10.1007/bf01218359] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Prospects for a new biologically based strategy of cancer treatment are being discussed. While physically and chemically based therapies, such as radio- and chemotherapy, are not directed against cancer tissue only and have a suppressive effect on the immune system, immunotherapy and gene therapy, which are discussed here, try to be more selective and to stimulate rather than suppress antitumor immune mechanisms. On the basis of personal experience with these new technologies, good future prospects are predicted for the application of cancer vaccines and immune T lymphocytes for active specific immunization (ASI) and adoptive immunotherapy (ADI) respectively. While ASI strategies aim at micrometastases being affected by activated host immune T cells, and might find a place for postoperative adjuvant treatment in high-risk cancer patients, cellular therapies such as ADI do not require an intact host immune system and could therefore also find application in advanced stages of disease. In spite of the exciting new perspectives of immuno- and gene therapy for the cancer patient, this therapy is not yet a defined discipline and requires years of further research.
Collapse
Affiliation(s)
- V Schirrmacher
- Abteilung Zelluläre Immunologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
| |
Collapse
|